ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2493

Efficacy and Safety of Tofacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Prior Therapies

John Tesser1, Ahmet Gül2, Ewa Olech3, Kurt Oelke4, Tatjana Lukic5, Christopher W Murray6, Chuanbo Zang6 and Liza Takiya6, 1Arizona Arthritis & Rheumatology Associates, Glendale, AZ, 2Istanbul University, Istanbul, Turkey, 3UNLV School of Medicine, Las Vegas, NV, 4Rheumatic Disease Center, Glendale, WI, 5Pfizer Inc, New York, NY, 6Pfizer Inc, Collegeville, PA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: DMARDs, drug treatment, rheumatoid arthritis (RA) and tofacitinib

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Patients (pts) with RA generally receive conventional synthetic DMARDS (csDMARDs) as first-line therapy, and inadequate responders (IR) to csDMARDs generally receive biological DMARDs (bDMARDs). We evaluated the efficacy and safety of tofacitinib in 3 RA pt populations (popns) who had incomplete response or were intolerant to prior lines of therapy (both referred to as IR).

Methods: Data from pts who were 1) non-MTX csDMARD-IR but not bDMARD-IR; 2) MTX-IR but not bDMARD-IR; and 3) bDMARD-IR (referred to as non-MTX csDMARD-IR, MTX-IR, and bDMARD-IR) were pooled from 8 Phase 2 and 6 Phase 3 trials evaluating the efficacy and safety of tofacitinib 5 or 10 mg BID vs placebo (PBO) in RA. Pts may have received >1 prior csDMARD, and in ~60% of the studies tofacitinib was given in combination with a csDMARD, commonly MTX. Month (M)3 efficacy outcomes included % of pts achieving ACR20/50/70 responses or Disease Activity Score in 28 joints, erythrocyte sedimentation rate (DAS28-4[ESR])<2.6 (remission), and change from baseline (BL) in DAS28-4(ESR) or HAQ-DI scores. No multiplicity adjustments were made. Crude incidence rates (CIR; unique pts with events/100 pt-yrs) based on adverse events (AEs) through M24 were calculated as safety outcomes.

Results: The non-MTX csDMARD-IR, MTX-IR, and bDMARD-IR popns comprised a total of 537, 3113, and 782 pts, respectively (Table; the non-MTX csDMARD-IR and bDMARD-IR popns were substantially smaller). Prior csDMARDs received by the total non-MTX csDMARD-IR, MTX-IR, and bDMARD-IR popns were chloroquine (17.7%, 13.8%, 4.1%), hydroxychloroquine (37.2%, 21.2%, 19.8%), leflunomide (19.4%, 20.5%, 24.2%), MTX (7.3% [not IR to MTX], 100%, 95.5%), sulfasalazine (31.1%, 26.8%, 18.0%), and others (8.0%, 10.7%, 10.4%), respectively. BL characteristics were similar between non-MTX csDMARD-IR, MTX-IR, and bDMARD-IR popns except for mean RA duration (5.2–7.2, 8.1–8.6, and 11.6–12.2 yrs, respectively). Most pts were female (80.3–85.4%), mean age range was 49.7–54.6 yrs, and mean DAS28-4(ESR) score ranged from 6.2–6.5. Significantly higher ACR response rates and greater changes from BL in DAS28-4(ESR) and HAQ-DI scores at M3 were recorded with tofacitinib 5 and 10 mg BID in all popns vs PBO (Table). A trend was observed for numerically higher proportions of non-MTX csDMARD-IR pts achieving efficacy outcomes vs MTX-IR and bDMARD-IR popns. CIRs for TEAEs, SAEs, and DC due to AEs were numerically lower in the non-MTX csDMARD-IR popn vs the MTX-IR popn and both popns had lower CIRs vs the bDMARD-IR popn. For numerical differences, 95%CIs generally overlap. AEs of special interest are reported (Table).

Conclusion: Tofacitinib is associated with improved efficacy and most safety outcomes vs PBO in each of the non-MTX csDMARD-IR, MTX-IR, and bDMARD-IR popns, and may be more efficacious when used in earlier lines of therapy.


Disclosure: J. Tesser, Pfizer Inc, 2,Pfizer Inc, 5,Pfizer Inc, 8; A. Gül, AbbVie, Bristol-Myers Squibb, MSD, Novartis, Pfizer Inc, Roche, Servier, UCB, Xoma, 5; E. Olech, Aurinia, Biogen Idec, Bristol-Myers Squibb, Pfizer Inc, 2,AbbVie, Amgen, Crescendo, Pfizer Inc, 8; K. Oelke, Novartis, 5,AbbVie, Amgen, Bristol-Myers Squibb, Novartis, Pfizer Inc, Regeneron, Sanofi, UCB, 8; T. Lukic, Pfizer Inc, 1,Pfizer Inc, 3; C. W. Murray, Pfizer Inc, 1,Pfizer Inc, 3; C. Zang, Pfizer Inc, 1,Pfizer Inc, 3; L. Takiya, Pfizer Inc, 1,Pfizer Inc, 3.

To cite this abstract in AMA style:

Tesser J, Gül A, Olech E, Oelke K, Lukic T, Murray CW, Zang C, Takiya L. Efficacy and Safety of Tofacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Prior Therapies [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/efficacy-and-safety-of-tofacitinib-in-patients-with-rheumatoid-arthritis-and-inadequate-response-or-intolerance-to-prior-therapies/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-tofacitinib-in-patients-with-rheumatoid-arthritis-and-inadequate-response-or-intolerance-to-prior-therapies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology